Agomelatine in treating generalized anxiety disorder

Area of Science:

• Pharmacology and Psychiatry
• Clinical Efficacy of Novel Antidepressants

Background:

• Generalized Anxiety Disorder (GAD) is a prevalent, disabling condition affecting 4.3-5.9% of the population.
• Numerous treatments exist for GAD, including pharmacotherapies like antidepressants and non-pharmacological interventions.
• Agomelatine, a melatonergic agonist and 5-HT2C antagonist, is approved for major depressive episodes.

Purpose of the Study:

• To evaluate the short-term efficacy of Agomelatine in treating GAD.
• To assess the long-term efficacy and relapse prevention capabilities of Agomelatine.
• To compare Agomelatine's efficacy and tolerability against escitalopram in GAD patients.

Main Methods:

• Two short-term, placebo-controlled studies assessed Agomelatine's acute efficacy.
• One relapse prevention study evaluated long-term treatment effectiveness.
• A comparative arm included escitalopram to benchmark efficacy and sleep restoration.

Main Results:

• Agomelatine demonstrated significant efficacy in treating both GAD and somatic anxiety.
• Comparable efficacy was observed between Agomelatine and escitalopram for GAD.
• Agomelatine significantly improved sleep restoration compared to escitalopram, with good tolerability and low discontinuation rates.

Conclusions:

• Agomelatine is a viable and effective treatment option for GAD and somatic anxiety.
• The drug offers superior sleep restoration benefits compared to escitalopram.
• Agomelatine exhibits good tolerability, evidenced by low discontinuation rates and minimal transient liver enzyme elevations.